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AbsTRACT
The syndrome of uraemic cardiomyopathy, characterised by 
left ventricular hypertrophy, diffuse fibrosis and systolic and 
diastolic dysfunction, is common in chronic kidney disease 
and is associated with an increased risk of cardiovascular 
morbidity and mortality. The pathophysiological 
mechanisms leading to uraemic cardiomyopathy are not 
fully understood. We suggest that coronary microvascular 
dysfunction may be a key mediator in the development of 
uraemic cardiomyopathy, a phenomenon that is prevalent 
in other myocardial diseases that share phenotypical 
similarities with uraemic cardiomyopathy such as 
hypertrophic cardiomyopathy and heart failure with 
preserved ejection fraction. Here, we review the current 
understanding of uraemic cardiomyopathy, highlight 
different methods of assessing coronary microvascular 
function and evaluate the current evidence for coronary 
microvascular dysfunction in chronic kidney disease.
InTRoduCTIon
Chronic kidney disease (CKD) is common, affecting 
one in seven of Western populations.w1 Usually, it is 
mild and there is little risk of progression to end-stage 
renal disease (ESRD), but the risk of adverse cardiovas-
cular events is elevated. There is a well-documented 
graded inverse relationship between cardiovascular 
risk and estimated glomerular filtration rate (eGFR) 
that is independent of age, sex and other risk factors.1 
Patients with CKD have an increased risk of coronary 
artery disease and an even higher risk of death from 
heart failure, arrhythmias and sudden death, which 
rises steeply with more severe CKD.2 In ESRD, the 
individual cardiovascular risk is extreme but the public 
health burden lies in early-stage CKD because of its 
much higher prevalence.
Pathological structural and functional remodelling 
occurs in the heart and vascular system in CKD. Left 
ventricular hypertrophy (LVH) is found in over 70% 
of patients with ESRD and other manifestations of 
heart muscle disease such as focal scarring and diffuse 
interstitial fibrosis (DIF) frequently occur, comprising 
the phenotype of uraemic cardiomyopathy.3 These 
findings are also present to a lesser degree in early-
stage disease.4 Hypertension is near universal. Vascular 
calcification is common and results from accelerated 
atherosclerosis (intimal disease) and arteriosclerosis 
(medial disease).5 Regardless of the vascular bed 
affected, these changes confer elevated cardiac risk by 
increasing arterial stiffness, which can be measured by 
pulse wave velocity and augmentation index.5 These 
arterial changes increase LV afterload which, together 
with humoral hypertrophic and profibrotic stimuli, 
lead to the syndrome of uraemic cardiomyopathy.5 As 
eGFR declines, the severity of this myocardial disease 
increases, possibly explaining the very high risk of 
death due to heart failure and sudden (presumed 
arrhythmic) cardiac death in ESRD.
uRAemIC CARdIomyopAThy
The syndrome of uraemic cardiomyopathy, charac-
terised by LVH, DIF, focal scarring and systolic and 
diastolic dysfunction, is highly prevalent in ESRD.2 3 
Uraemic cardiomyopathy has been well described in 
recent years, mainly using cardiac MRI (CMR).3 6 7 
The increased LV mass seen in ESRD is due to both 
myocyte hypertrophy and an expansion of the inter-
stitial space caused by DIF. Myocardial biopsy studies 
show that many subjects with ESRD have myocardial 
appearances resembling the dilated phase of hyper-
trophic cardiomyopathy (HCM) with severe myocyte 
hypertrophy, myocyte disarray and extensive DIF.8 
This fibrotic process can be demonstrated non-in-
vasively on CMR by T1 mapping; a technique that 
quantifies the relaxation time of protons on inver-
sion recovery prepared images (T1 times) by using 
analytical expression of image-based signal intensi-
ties.w2 T1 relaxation times increase with interstitial 
expansion due to oedema, infarction, infiltration and 
fibrosis, and thus provide a sensitive, though non-spe-
cific marker of different myocardial disease states.w2 
Interstitial fibrosis, identified by elevated T1 times, 
correlates with histological specimens in hypertro-
phic and dilated cardiomyopathy and valvular heart 
disease.w3 Patients with ESRD also have increased T1 
times, in keeping with these other myocardial disease 
states.6 7 The fibrotic process occurs early in CKD, 
with elevated T1 times documented in patients with 
stages 2–3 CKD compared with age-matched and 
sex-matched controls.4 DIF is probably responsible 
for reduced systolic function, reflected by reduced 
markers of deformation,w4 but causes severe diastolic 
dysfunction as tissue collagen deposition affects visco-
elasticity of the myocardium leading to impaired 
relaxation, diastolic recoil and passive stiffness.w5 It is 
believed to be a major cause of the clinical syndrome 
of heart failure and of the increased risk of arrhythmo-
genesis seen in uraemic cardiomyopathy.2
medIAToRs of AdveRse CARdIAC 
RemodellIng In CKd
The development of uraemic cardiomyopathy is likely 
to be multifactorial. Haemodynamic factors include 
increased afterload due to hypertension and arterial 
stiffness, and increased preload due to anaemia and 
sodium overload.2 A wide range of humoral and 
local factors are involved. Activation of the renin–
angiotensin–aldosterone system, hyperuricaemia, 
uraemic toxins such as asymmetric dimethylarginine, 
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hyperphosphataemia, abnormal bone mineral metabolism, elevated 
levels of hormones that regulate phosphate (parathyroid hormone 
and fibroblast growth factor-23 (FGF-23)), oxidative stress and 
chronic low-grade inflammation have all been implicated in the 
development of myocardial hypertrophy, fibrosis and increased 
cardiovascular mortality.2
A common consequence of these disparate mediators may be 
the development of pathological changes in the coronary micro-
circulation, a phenomenon that is evident in other myocardial 
disease states,w6 and requires further investigation.
The CoRonARy mICRoCIRCulATIon And myoCARdIAl 
dIseAse
Chilian proposed an elegant model of the coronary circulation 
consisting of three anatomically distinct but functionally inter-
linked compartments (figure 1).w7
The proximal compartment consists of large epicardial coronary 
arteries that function as capacitance vessels and respond to shear 
forces by endothelial mediated dilatation. The middle compartment 
consists of pre-arterioles that are characterised by a measurable pres-
sure drop along their length. The distal compartment consists of 
the intramural arterioles that have diameters <100 µm, have high 
resting tone and are responsible for the majority of coronary vascular 
resistance.9 They dilate in response to changes in myocardial oxygen 
consumption. Vasoactive mediators such as adenosine and hydrogen 
peroxide act directly on these vessels to produce vasodilatation.w8 
Endothelium-dependent mechanisms involving nitric oxide and 
endothelium derived relaxing factors are also important, with 
animal studies showing attenuated vasodilatation of the coronary 
microvasculature when nitric oxide synthesis is inhibited.w8 Finally, 
the capillary bed delivers oxygen and substrates to the myocytes. 
Thus, the coronary circulation matches myocardial oxygen demand 
with supply via a complex interplay between myogenic tone, meta-
bolic signals, circulating hormones and the intrinsic properties of 
the endothelium.w7
Abnormalities of all of these coronary vessels are seen in 
uraemia with atherosclerosis and medial thickening and calci-
fication of the epicardial vessels, and medial hypertrophy and 
a reduction in the cross-sectional surface area of the pre-arte-
rioles.5 Myocyte–capillary mismatch and reduced LV capillary 
density have also been demonstrated in uraemic hearts in both 
animal models and postmortem human studies.w9 w10
Abnormalities of coronary microvascular function are evident 
in myocardial disease states such as HCM and heart failure with 
preserved ejection fraction (HFpEF) that, like uraemic cardio-
myopathy, are characterised by hypertrophy and fibrosis. In 
HCM, studies using positron emission tomography (PET) have 
documented impaired microvascular function.w11 This predicts 
clinical consequences including reduced LV systolic function, 
adverse ventricular remodelling, ventricular arrhythmias, clinical 
heart failure and cardiovascular death.9w11 Similarly in HFpEF, 
coronary microvascular dysfunction (CMD) is common with a 
recent multicentre study identifying CMD in 75% of patients. 
This was associated with kidney damage, as measured by albu-
minuria, as well as a higher N-terminal pro-brain natriuretic 
peptide and systemic arterial dysfunction.w6
Although not fully understood, a paradigm is emerging which 
holds that risk factors such as obesity, hypertension, hypergly-
caemia and we suggest kidney dysfunction cause CMD, probably 
as a result of inflammation and oxidative stress. The consequent 
figure 1 Functional anatomy of the coronary circulation. Adapted from De Bruyne et al.w6
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failure to match myocardial blood flow (MBF) with demand 
results in widespread ischaemia, DIF, ventricular remodelling 
and systolic and diastolic dysfunction.w12 In CKD, the effect 
is likely to be exacerbated by hypertension, increased arterial 
stiffness and humoral factors such as FGF-23 and aldosterone 
leading to the clinical syndrome of uraemic cardiomyopathy.5 It 
is not clear if CMD is the cause or consequence of myocardial 
disease in uraemic cardiomyopathy. However, it is plausible that 
the relationship between myocardial fibrosis and CMD is recip-
rocal and a vicious circle is initiated in which both factors exac-
erbate each other causing progressive ischaemia and myocardial 
dysfunction leading to heart failure, arrhythmia and death 
(figure 2).w12
meThods of AssessIng CoRonARy mICRovAsCulAR 
funCTIon
The coronary microcirculation cannot be directly visualised in 
vivo. All assessments depend on indirect measures of micro-
vascular function. Coronary flow reserve (CFR) is the most 
widely reported parameter and has been measured using many 
different techniques (figure 3), which are summarised below 
and in table 1. To calculate CFR, hyperaemia is induced, usually 
with a pharmacological vasodilator, and CFR is measured as 
the ratio of maximal hyperaemic to resting flow. Adenosine 
is the most commonly used agent, as it is safe with a rapid 
onset and offset of action.w13 In normal subjects, coronary 
flow can increase up to fivefold and should at least double 
with hyperaemic stimuli. Thus, a CFR <2 is considered abnor-
mal.w13 w14 CFR reflects both epicardial coronary artery 
disease as well as microvascular function. Therefore, exclu-
sion of significant coronary artery disease is required before 
reduced CFR can be attributed to CMD.9 This is often difficult 
without angiography and is a limitation of many studies. A 
diagnostic algorithm for CMD in uraemic cardiomyopathy is 
suggested in figure 4.
Invasive coronary angiography
CFR can be assessed during invasive coronary angiography. Two 
different methods exist but both expose patients to infrequent 
but significant risks including vascular injury, contrast nephrop-
athy and death.
doppler guidewire
An angioplasty wire tipped with a high frequency piezoelectric 
Doppler transducer can be used to measure flow velocities in a 
coronary artery at rest and at hyperaemia. CFR is calculated as 
the ratio of hyperaemic/resting flow.w14
Intracoronary thermodilution
CFR can be assessed via thermodilution. A pressure wire is 
positioned in the distal third of a target vessel. The shaft of 
the pressure wire acts as a proximal thermistor while the 
sensor at its tip acts as a distal thermistor. Normal saline at 
figure 2 Proposed mechanism of uraemic cardiomyopathy. FGF-23, fibroblast growth factor-23; PTH, parathyroid hormone; RAAS, renin-
angiotensin-aldosterone system.
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room temperature is injected down the coronary artery and its 
transit time is measured by thermodilution. CFR is the ratio of 
hyperaemic transit time/baseline transit time. This technique 
correlates well with Doppler flow derived CFR.w15
positron emission tomography
The non-invasive ‘gold-standard’ method of assessing CFR is 
quantitative PET. Absolute values of MBF at rest and during 
hyperaemia can be calculated. Advantages of PET include 
figure 3 Different methods of assessing CFR: intracoronary Doppler angiography (top right) showing CFR of 1.8 in a patient with coronary artery 
disease, PET (top left), MRI coronary sinus flow (bottom left) and Doppler transthoracic echocardiogram (bottom right) showing CFR of 2.12 in a 
patient with chronic kidney disease stage 4. Adapted from Amier et al, w16 Feher et al w17 and Nakamori et al.w18 CFR, coronary flow reserve; PET, 
positron emission tomography.
Table 1 Summary of advantages and disadvantages of different modalities used to assess coronary flow reserve
modality Advantages disadvantages
Invasive angiography (Doppler and 
thermodilution)
1. Definitive exclusion of epicardial coronary artery disease
2. Widely available
1. Invasive procedure
2. Ionising radiation
Positron emission tomography 1. Non-invasive
2. Can assess myocardial ischaemia and scar
3. Allows calculation of regional and global myocardial blood 
flow
1. Ionising radiation
2. Not widely available in UK
Coronary sinus flow 1. Non-invasive
2. Sequences and analysis are quick to perform
1. Contraindications to MRI limit its widespread use
First pass perfusion 1. Non-invasive
2. Can assess myocardial ischaemia and scar
3. Myocardial viability can be ascertained
1. Requires gadolinium limiting its utility in chronic kidney disease
2. Scan sequences can be lengthy to perform and analyse
3. Contraindications to MRI limit its widespread use
Stress T1 mapping 1. Non-invasive
2. Provides additional myocardial tissue characterisation
1. Contraindications to MRI limit its widespread use
2. Not well validated
Doppler transthoracic echo 1. Non-invasive
2. Cheap
3. Portable
1. Only assesses left anterior descending artery territory
Myocardial contrast echo 1. Non-invasive
2. Cheap
3. Portable
4. Allows calculation of regional and global myocardial blood 
flow
1. Requires good acoustic windows
 o
n
 18 July 2019 by guest. Protected by copyright.
http://heart.bmj.com/
H
eart: first published as 10.1136/heartjnl-2019-315138 on 25 June 2019. Downloaded from 
5Radhakrishnan A, et al. Heart 2019;0:1–8. doi:10.1136/heartjnl-2019-315138
Review
its ability to assess regional blood flow, myocardial scar and 
myocardial ischaemia as well as CFR.10 Disadvantages include 
exposure to ionising radiation, high cost, difficulties in accessing 
radio-isotopes and the relative unavailability of the technique.
mRI
MRI is emerging as a useful tool for the non-invasive assessment 
of CFR, although it remains less validated than other imaging 
modalities. Methods include:
Coronary sinus flow
The majority of blood from epicardial ventricular veins drains 
into the coronary sinus, which can be visualised on MRI using 
velocity encoded cine sequences. CFR is the ratio of blood in the 
coronary sinus after hyperaemia compared with baseline.w16
first pass perfusion
Myocardial perfusion is recorded in dedicated basal, mid-ven-
tricular and apical short axis slices at rest and during stress. 
The ratio of the maximal up-slopes of signal intensity during 
vasodilatation over resting condition is defined as myocardial 
perfusion reserve.10 Perfusion defects can be identified to help 
localise coronary artery lesions and assessments of viability can 
be made using late gadolinium enhancement. However, the need 
for gadolinium limits its utility in CKD.
stress T1 mapping
T1 relaxation times of tissues are prolonged by increased water 
content. Coronary vasodilatation, by increased myocardial blood 
volume, would be expected to prolong T1 times.w17 Using this 
principle, measurement of rest and stress T1 times provide an 
indirect indication of increased MBF and myocardial perfusion 
reserve.w17
doppler transthoracic echocardiography
CFR can be measured using Doppler transthoracic echocardi-
ography (TTE) and correlates well with invasive Doppler and 
PET.w6 w14 The mid to distal left anterior descending artery 
(LAD) can be identified in a modified apical two-chamber view 
using a high frequency transducer and appropriate machine 
settings to identify low velocity flow. Pulse wave Doppler signals 
can be measured in the LAD at rest and during hyperaemia to 
calculate CFR.w14 This technique is feasible in most patients, 
including those who are obese, as it is less reliant on good 
acoustic windows due to the superficial location of the LAD.w6
figure 4 Proposed diagnostic algorithm for coronary microvascular dysfunction (CMD) in uraemic cardiomyopathy. PET, positron emission 
tomography; TTE, transthoracic echocardiography.
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myocardial contrast echo
Myocardial contrast echocardiography uses protein microbub-
bles that have a lower diameter than the red blood cell, resist 
arterial pressure and remain intravascular in the intact circula-
tion. These qualities enable direct quantification of microvas-
cular perfusion and allow absolute MBF as well as CFR to be 
calculated.10
Cmd In CKd: The evIdenCe so fAR
A structured PubMed database search was carried out for arti-
cles between 1966 and 2019 using the keywords ‘coronary flow 
reserve’, ‘myocardial perfusion reserve’ or ‘coronary micro-
vascular dysfunction’ combined with ‘chronic kidney disease’, 
‘end-stage kidney disease’, ‘end-stage renal disease’ or ‘uraemic 
cardiomyopathy’. A total of 396 articles were identified. After 
removal of duplicates, 20 studies were considered relevant to 
this topic. Included studies are summarised in table 2.
There are limited conflicting data on coronary microvascular 
function in CKD. CMD appears common with prevalence rates 
of 24%–90%.11–16 The largest angiographic study examined 
CFR in 605 patients stratified as normal or reduced kidney 
function, using an arbitrary cut-off eGFR of 60 mL/min. Crude 
analysis indicated a reduced CFR in patients with CKD but this 
was not statistically significant after correction for age, gender 
and comorbidities including hypertension and diabetes.17 By 
contrast, smaller angiographic studies have shown a significant 
decrease in CFR in patients with diabetic nephropathy and in 
ESRD, compared with healthy controls.18 19
Using PET, a study of 10 controls and 22 patients with CKD 
stages 3–5 showed a trend towards reduced CFR with increasing 
stage of CKD, but this did not reach statistical significance.20 
Similarly, retrospective calculation of CFR using PET in 435 
patients with stages 1–3 CKD also found there was no significant 
difference in CFR after correction for cardiovascular risk factors 
Table 2 Summary of studies on coronary microvascular dysfunction in chronic kidney disease (CKD)
study year Country population modality findings
Ragosta et al18 2004 USA Controls (n=32)
Patients with diabetes with no kidney disease 
(n=11)
Patients with diabetic nephropathy (n=21)
Doppler 
angiography
Significantly lower CFR in patients with diabetic 
nephropathy compared with other two groups.
Tok et al25 2005 Turkey Controls (n=14)
Patients on HD (n=10)
Doppler TTE Significantly lower CFR in HD patients.
Chade et al17 2006 USA GFR >60 mL/min (n=481)
GFR <60 mL/min (n=124)
Doppler 
angiography
Non-significant trend towards reduced CFR as eGFR 
falls.
Viganò et al26 2007 Italy Controls (n=17)
Renal transplant recipients (n=25)
Doppler TTE CFR impaired in half of cases.
Niizuma et al24 2008 Japan Controls (n=20)
Patients on HD (n=21)
Doppler TTE Significantly lower CFR in HD patients.
Caliskan et al12 2008 Turkey Controls (n=39)
HD (n=48)
Renal transplant recipients (n=27)
Doppler TTE Significantly lower CFR in ESRD and in renal transplant 
recipients. Lower CFR in ESRD than renal transplant 
recipients.
Bezante et al11 2009 Italy Patients with hypertension and normal renal 
function (n=64)
Patients with hypertension and renal impairment 
(n=12)
Doppler TTE Significantly lower CFR in patients with hypertension 
and renal impairment.
Koivuviita et al20 2009 Finland Controls (n=10)
CKD stages 3–5 (n=22)
PET Non-significant trend towards reduced CFR as eGFR 
falls.
Turiel et al27 2009 Italy Controls (n=25)
Renal transplant recipients (n=25)
Doppler TTE Significantly lower CFR in renal transplant recipients 
compared with controls.
Bozbas et al13 2009 Turkey Controls (n=26)
ESRD (n=30)
Renal transplant recipients (n=30)
Doppler TTE Significantly lower CFR in ESRD and in renal transplant 
recipients. Lower CFR in ESRD than renal transplant 
recipients.
Charytan et al21 2010 USA CKD stages 1–3 (n=435) PET Non-significant trend towards reduced CFR as eGFR falls
Akagun et al28 2011 Turkey Renal transplant recipients (n=20) Doppler TTE CFR <2 in 65%
Murthy et al29 2012 USA eGFR <60 mL/min (n=866) PET CFR <1.5 associated with increased risk of cardiac 
mortality.
Imamura et al23 2014 Japan Controls (n=15)
CKD stages 1–5 (n=175)
Doppler TTE Significant decrease in CFR as eGFR falls. Incremental 
reduction in CFR with albuminuria.
Shah et al14 2016 USA Dialysis-dependent patients (n=168) PET CFR <1.5 associated with increased risk of cardiac 
mortality.
Nakanishi et al15 2013 Japan eGFR <60 mL/min (n=139) Doppler TTE CFR <2 associated with worse cardiovascular outcomes.
Tona et al30 2016 Italy Simultaneous kidney pancreas transplant recipients 
(n=48)
Doppler TTE Lower CFR associated with worse cardiovascular 
outcomes.
Paz et al16 2017 USA ESRD awaiting transplant (n=131) PET CFR <2 in 58.8% of patients with ESRD.
Charytan et al22 2018 USA Controls (n=198)
CKD stages 1–5 (n=3748)
PET Significant decrease in CFR as CKD stage increases.
Nelson et al19 2019 USA Controls (n=15)
ESRD (n=15)
Doppler 
angiography
Significantly reduced CFR in ESRD compared with 
controls.
CFR, Coronary flow reserve; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HD, haemodialysis; PET, positron emission tomography; TTE, transthoracic 
echocardiography. 
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such as age, sex and blood pressure.21 The largest PET study 
to date is a retrospective analysis of 3946 patients who under-
went stress PET at a single US institution. This study demon-
strated a significant decrease in CFR as renal function declined, 
with the largest drop being in patients with CKD stage 4 and 
no significant further drop in stage 5 or those on dialysis.22 In 
patients undergoing cardiovascular assessment for renal trans-
plant by dipyridamole PET perfusion imaging, 59% of patients 
had a CFR <2 and even in those patients without any feature of 
infarction or ischaemia, 63% had abnormal CFR.16
Several studies have been performed using TTE. The rela-
tionship between albuminuria and CMD was investigated in a 
prospective Japanese study of 175 patients with CKD. Significant 
reductions in CFR with increasing stages of CKD were evident 
and patients with albuminuria, had significantly lower CFR at 
each stage of CKD.23 In patients with essential hypertension, the 
presence of CKD was associated with a 10-fold increase in the 
risk of CMD.11 Small studies of dialysis patients and controls 
have also shown reduced CFR measured by TTE in patients on 
haemodialysis compared with controls.24 25
There has been limited investigation into the effects of kidney 
transplantation on CFR. As kidney function is partially restored, 
one would expect an improvement in coronary microvascular 
function after kidney transplantation. This is suggested in 
cross-sectional data showing that CFR may be higher in trans-
plant recipients compared with patients with ESRD.12 13 Possible 
explanations are that some of the microvascular changes seen in 
ESRD are reversible or alternatively that repeated haemodialysis 
causes microvascular dysfunction. Despite this, rates of CMD 
remain high after kidney transplant, with 8%–65% of renal 
transplant recipients having a CFR <2.26–28
The mechanisms of CMD in CKD are not fully understood. 
Patients with CKD demonstrate increased resting coronary 
flow but an impaired response to vasodilator stimuli, leading 
to reduced CFR.11 14 18 The reduced response to adenosine and 
other vasodilatory stimuli is likely to be due to factors such as 
reduced cross-sectional area of the microcirculation, increased 
coronary sympathetic arteriolar tone, endothelial dysfunction 
and a reduced smooth muscle response which may be due to 
defects at both receptor and post receptor levels.w9 w18 w19 
Impaired myocardial vascular reserve and MBF autoregulation 
has been demonstrated in animal models of CKD.w20
The pRognosTIC Role of ReduCed CfR In CKd
Several studies have investigated the relationship between 
reduced CFR and prognosis in CKD. These are mainly retrospec-
tive and included patients with comorbidities such as diabetes 
and hypertension that are known to affect CFR. In a retrospec-
tive analysis of 866 patients with moderate to severe CKD who 
underwent stress PET, even after adjustment for clinical risk 
factors, LV systolic function, extent of ischaemia and scar, a 
CFR below the median (<1.5) was associated with a 2.1-fold 
increased risk of cardiovascular mortality.29 The same investiga-
tors also retrospectively examined a cohort of 186 patients with 
dialysis dependent ESRD and again found that CFR below the 
median (1.4) was associated with a significant increased risk of 
all-cause and cardiovascular mortality over a median follow-up 
period of 3 years. Log transformed CFR was independently asso-
ciated with all-cause and cardiovascular mortality.14 A prospec-
tive study using Doppler TTE assessed 139 patients with CKD, 
and identified that patients with CFR <2 had significantly 
higher rates of cardiac events and all-cause mortality even after 
adjustment for cardiovascular risk factors.15
There is very limited information on the role of CFR in 
predicting prognosis in renal transplant recipients. Data are 
conflicting with a small Turkish study (n=20) showing no prog-
nostic role for CFR measurement in kidney transplant patients.28 
By contrast, an Italian study of 48 patients who had undergone 
simultaneous kidney/pancreas transplant showed that a CFR <2 
was associated with increased risk of major adverse cardiovas-
cular events.30 However, it is difficult to draw any meaningful 
conclusions from these studies given the small numbers involved.
ConClusIons
CMD provides a plausible mechanism by which factors associated 
with impaired kidney function, including oxidative stress and inflam-
mation, might result in myocardial damage and dysfunction leading 
to the syndrome of uraemic cardiomyopathy. Current data on CMD 
in uraemic cardiomyopathy are limited and conflicting, hampered 
by the retrospective design of most studies. Consequently, there is 
a need for well-designed prospective studies of CMD in CKD, to 
identify whether CMD might be a key mediator in the development 
of uraemic cardiomyopathy. Future studies will need to investigate 
the utility of strategies to prevent or reduce CMD and thus fibrosis 
and ventricular dysfunction in CKD. Possible agents that may be 
effective in in this regard might include new biological agents acting 
on inflammatory cytokines, antioxidants and, further down the 
pathway, specific antifibrotic drugs. Given the prevalence of CKD 
in the general population, a better understanding of the mechanisms 
behind uraemic cardiomyopathy is a vital step towards improving 
the significant cardiovascular morbidity and mortality seen in CKD.
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